Korro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$KRRO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $KRRO alert in real time by email
8-K
0001703647falseNASDAQ00017036472025-03-182025-03-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2025

 

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-39062

47-2324450

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

60 First Street, 2nd floor, Suite 250

Cambridge, MA

 

02141

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (617) 468-1999

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.001 per share

 

KRRO

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 2.02. Results of Operations and Financial Condition.

On March 18, 2025, Korro Bio, Inc. issued a press release announcing its financial results for the year ended December 31, 2024. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

 

Description

 

 

 

99.1

 

Press Release issued by Korro Bio, Inc., dated March 18, 2025

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KORRO BIO, INC.

 

 

Date: March 18, 2025

By:

/s/ Ram Aiyar

 

 

 

 

 

Name: Ram Aiyar

 

 

Title: President and Chief Executive Officer

 

 


Get the next $KRRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KRRO

DatePrice TargetRatingAnalyst
1/10/2025$155.00Outperform
Oppenheimer
10/21/2024$153.00Strong Buy
Raymond James
8/14/2024$180.00Outperform
William Blair
3/28/2024$100.00 → $115.00Buy
H.C. Wainwright
2/27/2024$120.00Outperform
BMO Capital Markets
12/4/2023$100.00Buy
H.C. Wainwright
11/29/2023$70.00Outperform
RBC Capital Mkts
11/10/2023$180.00Overweight
Piper Sandler
More analyst ratings

$KRRO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Korro Reports Full Year 2024 Financial Results and Provides Business Updates

    —Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025  —U.S. Food and Drug Administration (FDA) Granted Orphan Drug Designation to KRRO-110 for the treatment of AATD   —Executing 3-2-1 strategy through end of 2027 with the goal of establishing three clinical-stage development programs, targeting two tissue types with a single RNA-editing platform; Second development candidate expected to be announced in 2025  —Strengthened leadership team with the formation of Clinical Advisory Board and key additions to board and management team  —Ended 2024 with a strong balance

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

    CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). "Receiving orphan drug designation from the FDA underscores the growing need for new treatments for patients living with AATD," said Kemi Olugemo, MD, Chief Medical Officer at Korro. "KRRO-110 has the potential to treat both liver and lung

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KRRO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$KRRO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$KRRO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$KRRO
SEC Filings

See more

$KRRO
Leadership Updates

Live Leadership Updates

See more
  • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

    CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

    $CAMP
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

    - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$KRRO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more